Q-omics provides the consensus-scored KCNJ1 profile across patient tissues and cancer cell-line models. KCNJ1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KCNJ1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, KCNJ1 RNA expression shows 14,351 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where KCNJ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ1 survival associations across molecular data types. KCNJ1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ1 RNA expression–survival associations across cancer types. High KCNJ1 expression shows unfavorable associations in UVM, ACC and LUSC, but favorable associations in SKCM, ESCA and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for KCNJ1 RNA expression.
This table summarizes KCNJ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCNJ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ1 shows lower tumor expression in KIRC, KICH, KIRP, THCA, BRCA and LUSC. The KIRC box plot shows higher KCNJ1 RNA expression in normal versus tumor tissue (log2 FC = −7.260, t-test p < 0.001).
This table shows molecular features associated with KCNJ1 in patient tissues and cancer cell lines. In patient samples, KCNJ1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
